Evaluation of the Relative Bioavailability of LY03010 Compared to Paliperidone Palmitate After Intramuscular Injection in Healthy Subjects

The primary objective of this study is to evaluate the **relative bioavailability** of LY03010 compared to Xeplion® following a single intramuscular injection in healthy subjects. This assessment is clinically relevant as it provides insights into the pharmacokinetic profile of LY03010, which is crucial for determining its potential efficacy and safety in the treatment of **schizophrenia**. Understanding the bioavailability of LY03010 relative to an established treatment like Xeplion® can inform dosing strategies and therapeutic decision-making in clinical practice.

The clinical trial focuses on individuals diagnosed with **schizophrenia**. The study population includes both male and female participants, encompassing an age range classified under category code "3," which typically refers to adults. The trial involves a vulnerable population, indicating that special considerations are in place to ensure the safety and ethical treatment of participants. The sponsor has not provided information regarding the total number of participants or specific lifestyle considerations such as diet, physical activity, or habits. The selection process for the trial population and any key inclusion or exclusion criteria have not been disclosed by the sponsor.

The clinical trial is designed as a **randomized**, open-label, single-dose, parallel-group study to evaluate the relative bioavailability of LY03010 compared to Xeplion® following intramuscular injection in healthy subjects. The study targets individuals with **schizophrenia** and is categorized as a Phase 2 trial. The trial is expected to commence recruitment on January 2, 2023, and conclude by March 31, 2023. Participants will be randomly assigned to receive either LY03010 or Xeplion® to assess the pharmacokinetic profile of the investigational product.

The trial will include several key study visits. Initially, a screening visit will be conducted to determine participant eligibility based on predefined inclusion and exclusion criteria. Following successful screening, participants will be enrolled and receive a single dose of the assigned treatment. Subsequent follow-up visits will be scheduled to monitor the participants' health status and collect necessary data for the study's endpoints. The end-of-study visit will mark the completion of the trial for each participant, during which final assessments will be conducted.

The expected duration of participant involvement in the study is approximately three months, aligning with the overall trial timeline. Participants may be subject to early termination from the study if they experience adverse events that compromise their safety, fail to comply with study procedures, or withdraw consent. The study's design and procedures are structured to ensure the collection of reliable data while maintaining participant safety and adherence to ethical standards.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to begin recruitment on January 2, 2023, with an estimated end date of March 31, 2023. The efficacy assessment will focus on specific parameters or endpoints, although these are not detailed in the provided data. The methods and schedule for measuring, collecting, and analyzing these efficacy parameters are not specified. The trial will adhere to standard clinical trial protocols to ensure the reliability and validity of the efficacy assessments. The trial phase indicates an intermediate stage of testing, typically involving a larger group of participants to evaluate the effectiveness and further assess safety. The absence of detailed endpoints and methods suggests that these will be defined in accordance with regulatory standards and best practices in clinical research.